| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 21.954 | 1.527 | 4.055 | 4.134 | 2.125 | 5.508 | 21.190 | 30.625 | 16.079 | 3.950 |
| Total Income - EUR | 21.954 | 1.527 | 4.055 | 4.134 | 2.125 | 5.508 | 21.190 | 30.625 | 16.079 | 3.950 |
| Total Expenses - EUR | 18.918 | 18.010 | 9.371 | 12.853 | 2.759 | 6.126 | 10.683 | 9.574 | 11.148 | 3.709 |
| Gross Profit/Loss - EUR | 3.036 | -16.483 | -5.316 | -8.719 | -633 | -618 | 10.507 | 21.051 | 4.931 | 240 |
| Net Profit/Loss - EUR | 2.378 | -16.529 | -5.437 | -8.843 | -697 | -783 | 9.884 | 20.161 | 4.024 | 92 |
| Employees | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 |
Check the financial reports for the company - New Psihomedica Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 3.686 | 2.593 | 2.234 | 2.193 | 2.150 | 2.109 | 2.318 | 2.069 | 2.063 | 2.051 |
| Current Assets | 63.915 | 46.477 | 36.482 | 26.946 | 16.738 | 19.351 | 28.705 | 31.568 | 37.013 | 37.168 |
| Inventories | 767 | 759 | 424 | 417 | 409 | 401 | 392 | 0 | 0 | 0 |
| Receivables | 126 | 345 | 2 | 2 | 1.063 | 0 | 846 | 1.225 | 617 | 466 |
| Cash | 63.022 | 45.374 | 36.056 | 26.528 | 15.266 | 18.950 | 27.467 | 30.344 | 36.396 | 36.702 |
| Shareholders Funds | 62.035 | 44.873 | 38.677 | 29.124 | 18.065 | 16.939 | 26.448 | 29.264 | 33.198 | 33.105 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 5.566 | 4.197 | 39 | 15 | 823 | 4.521 | 4.576 | 4.374 | 5.877 | 6.114 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - New Psihomedica Srl